Compare VIRC & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIRC | PMVP |
|---|---|---|
| Founded | 1950 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.5M | 76.8M |
| IPO Year | 1995 | 2020 |
| Metric | VIRC | PMVP |
|---|---|---|
| Price | $5.51 | $1.17 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.30 | N/A |
| AVG Volume (30 Days) | 28.3K | ★ 414.3K |
| Earning Date | 04-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $199,652,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.77 | N/A |
| P/E Ratio | $37.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.16 | $0.91 |
| 52 Week High | $9.07 | $1.88 |
| Indicator | VIRC | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 29.51 | 34.57 |
| Support Level | $5.16 | $1.12 |
| Resistance Level | $6.40 | $1.26 |
| Average True Range (ATR) | 0.16 | 0.07 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 6.76 | 2.27 |
Virco Manufacturing Corp is engaged in designing, production and distributing quality furniture for the commercial and education markets. The company manufactures an assortment of products, including mobile tables, mobile storage equipment, desks, computer furniture, chairs, activity tables, folding chairs, and folding tables. Its primary furniture lines are constructed of tubular metal legs and frames, combined with wood and plastic tops, plastic seats and backs, upholstered seats and backs, and upholstered rigid polyethylene and polypropylene shells.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.